Managers / Q1 2019 · view latest →
TRV GP II, LLC
CIK 0001614073 · THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON, MA, 02116 · 617-585-2000
Summary
Trv GP II, LLC reported $153M in U.S.-listed holdings across 3 positions for Q1 2019.
The portfolio is heavily concentrated: Blueprint Medicines Corporation alone accounts for 45.9% of reported value.
Compared with Q4 2018, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $153M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SAGE THERAPEUTICS, INC. | SOLD OUT | −37.4K | 0 | −$4M | $0 |
| JOUNCE THERAPEUTICS, INC. | HELD | +0 | 10.23M | +$29M | $63M |
| BLUEPRINT MEDICINES CORPORATION | HELD | +0 | 878.9K | +$23M | $70M |
| ALLENA PHARMACEUTICALS, INC. | HELD | +0 | 2.79M | +$4M | $20M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORPORATION | COM | 45.87% | $70M | 878.9K |
| 2 | JOUNCE THERAPEUTICS, INC. | COM | 41.35% | $63M | 10.23M |
| 3 | ALLENA PHARMACEUTICALS, INC. | COM | 12.77% | $20M | 2.79M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $1M | 1 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $5M | 2 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $10M | 2 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $24M | 2 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $23M | 2 | Nov 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $34M | 2 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $158M | 3 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $144M | 3 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $154M | 3 | Nov 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $135M | 3 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 3 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $97M | 2 | Feb 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $45M | 2 | Nov 4, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $62M | 2 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $153M | 3 | May 3, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $101M | 4 | Jan 28, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- Mark Levin028-18439
- Kevin P. Starr028-18438
- Robert I. Tepper028-18419
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.